Dupuytren’s disease and collagenase: evidence for a paradigm shift in management

Dupuytren’s disease (DD) is a common disease which leads to significant functional impairment of the hand. The recent introduction of Collagenase Clostridium Histolyticum (CCH) as a therapeutic option has changed the approach to disease management. Currently no management paradigm exists for treating Dupuytren’s disease within Australia. Methods: Databases were searched for Dupuytren’s disease patients receiving CCH. PRISMA guidelines were used to screen predefined classification of effectiveness, safety and recurrence of CCH. Results: In this review, 18 studies were included and analysed to evaluate the effectiveness, safety and recurrence of CCH. Conclusion: CCH has the potential as a non-surgical therapeutic option to expand the management paradigm for DD. This may minimise treatment time, cost and improve the public health care sector’s treatment of DD.